Glucagon, the counter-regulatory hormone to insulin, is secreted from pancreatic ␣ cells in response to low blood glucose. To examine the role of glucagon in glucose homeostasis, mice were generated with a null mutation of the glucagon receptor (Gcgr ؊/؊ ). These mice display lower blood glucose levels throughout the day and improved glucose tolerance but similar insulin levels compared with control animals. Gcgr ؊/؊ mice displayed supraphysiological glucagon levels associated with postnatal enlargement of the pancreas and hyperplasia of islets due predominantly to ␣ cell, and to a lesser extent, ␦ cell proliferation. In addition, increased proglucagon expression and processing resulted in increased pancreatic glucogen-like peptide 1 (GLP-1) (1-37) and GLP-1 amide (1-36 amide) content and a 3-to 10-fold increase in circulating GLP-1 amide. Gcgr ؊/؊ mice also displayed reduced adiposity and leptin levels but normal body weight, food intake, and energy expenditure. These data indicate that glucagon is essential for maintenance of normal glycemia and postnatal regulation of islet and ␣ and ␦ cell numbers. Furthermore, the lean phenotype of Gcgr ؊/؊ mice suggests glucagon action may be involved in the regulation of whole body composition.

The BETA2 (neuroD) gene is expressed in endocrine cells during pancreas development and is essential for proper islet morphogenesis. The objective of this study is to identify potential upstream regulators of the BETA2 gene during pancreas development. We demonstrated that the expression of neurogenin 3 (ngn3), an islet-and neuron-specific basic-helix-loop-helix transcription factor, partially overlaps that of BETA2 during early mouse development. More importantly, overexpression of ngn3 can induce the ectopic expression of BETA2 in Xenopus embryos and stimulate the endogenous RNA of BETA2 in endocrine cell lines. Furthermore, overexpression of ngn3 could cause a dose-dependent activation on the 1.0-kb BETA2 promoter in islet-derived cell lines. Deletion and mutation analyses revealed that two proximal E box sequences, E1 and E3, could bind to ngn3-E47 heterodimer and mediate ngn3 activation. Based on these results, we hypothesize that ngn3 is involved in activating the expression of BETA2 at an early stage of islet cell differentiation through the E boxes in the BETA2 promoter.The endocrine pancreas, which is organized as the islets of Langerhans, contains at least four distinct types of endocrine cells (␣, ␤, ␦, and PP). The differentiation and maturation of islet cells during development is a complex process controlled by a unique network of gene regulation. Recently, it has been demonstrated by gene targeting studies that several tissuespecific transcription factors, such as BETA2 (neuroD) (24, 25), PDX-1 (1, 27), Islet-1 (2), Nkx2.2 (42), PAX-6 (41), and PAX-4 (40), are involved in this process. These factors, alone or in concert, can activate the expression of genes encoding hormones, such as glucagon (9, 44), insulin (9, 25, 28), and somatostatin (3, 31). BETA2 (neuroD), a basic helix-loop-helix (bHLH) transcription factor, was isolated both as a transcriptional activator of the insulin gene (25) and as a differentiation factor of neurogenesis (17). BETA2 is selectively expressed in the developing endocrine pancreas, the small intestine, and the nervous system (17). It has been shown that BETA2 transactivates the insulin (25) and glucagon genes (9) by binding to the E box sequences localized in their promoters. Furthermore, the functional importance of BETA2 to pancreatic islet cell development has been demonstrated by loss-of-function studies (24). BETA2-deficient (BETA2 Ϫ/Ϫ ) mice die of severe diabetes caused by a major reduction in the number of ␤ cells and a lack of proper islet formation. These results indicate that BETA2 plays an important role in maintaining the differentiation of endocrine cells and proper islet morphogenesis. Results obtained from BETA2-deficient mice also imply that the upstream factors controlling BETA2 expression are likely to be involved in the early events which determine endocrine cell differentiation. So far, numbers of a novel family of genes, the neurogenin genes (ngn) (19, 39), have been reported to be good candidates for upstream regulators of the BETA2 gene. During n...

Purpose: Recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising antitumor agent. However, many hepatocellular carcinoma (HCC) cells show resistance to TRAILinduced apoptosis. Here, we report that sorafenib improves the antitumor effect of TRAIL-related agents in resistant HCC.Experimental Design: HCC cell lines (PLC5, Huh-7, Hep3B, and Sk-Hep1) were treated with sorafenib and/or TRAIL-related agents (TRAIL or LBY135) and analyzed in terms of apoptosis and signal transduction. In vivo efficacy was determined in nude mice with PLC5 xenografts.Results: Sorafenib, the only approved drug for HCC, sensitizes resistant HCC cells to an agonistic DR5 antibody (LBY135) and TRAIL-induced apoptosis in TRAIL-resistant HCC cells. We found that STAT3 played a significant role in mediating TRAIL sensitization. Our data showed that sorafenib downregulated phospho-STAT3 (pSTAT3) and subsequently reduced the expression levels of STAT3-related proteins (Mcl-1, survivin, and cyclin D1) in a dose-and time-dependent manner in TRAIL-treated HCC cells. Knockdown of STAT3 by RNA interference overcame apoptotic resistance to TRAIL in HCC cells, and ectopic expression of STAT3 in HCC cells abolished the TRAIL-sensitizing effect of sorafenib. Moreover, SHP-1 inhibitor reversed downregulation of pSTAT3 and apoptosis induced by sorafenib, and silencing of SHP-1 by RNA interference abolished the effects of sorafenib on pSTAT3. Notably, sorafenib increased SHP-1 activity in PLC5 cells. Finally, sorafenib plus LBY135 significantly suppressed PLC5 xenograft tumor growth.Conclusions: Sorafenib sensitizes resistant HCC cells to TRAIL-induced apoptosis at clinical achievable concentrations, and this effect is mediated via the inhibition of STAT3. Clin Cancer Res; 16(21); 5189-99. ©2010 AACR.